Screener
Rigel Pharmaceuticals RIGL Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Commitments | ||
| Stockholders’ equity: | ||
| Common stock | 18 | 18 |
| Additional paid-in capital | 1,414,394 | 1,414,322 |
| Accumulated other comprehensive (loss) income | (128) | 181 |
| Accumulated deficit | (1,014,387) | (1,023,041) |
| Total stockholders’ equity | 399,897 | 391,480 |
| Total liabilities and stockholders’ equity | $504,608 | $513,594 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's retained earnings?
- Rigel Pharmaceuticals (RIGL) reported retained earnings of -$1.01B in Q1 2026.
- How has Rigel Pharmaceuticals's retained earnings changed year-over-year?
- Rigel Pharmaceuticals's retained earnings increased by 26.4% year-over-year, from -$1.38B to -$1.01B.
- What is the long-term trend for Rigel Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's retained earnings has grown at a -4.8% compound annual growth rate (CAGR), from -$1.31B to -$1.02B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Rigel Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude